Condition (MeSH)
Tissue Adhesions
ClinicalTrials.gov lists 121 trials for Tissue Adhesions or a narrower condition beneath it. Shin Poong Pharmaceutical Co. Ltd. has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
121 of the 121 trials are tagged with Tissue Adhesions itself; the rest are tagged with a narrower condition beneath it.
When did Tissue Adhesions trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 9 |
| 2024 | 3 |
| 2023 | 5 |
| 2022 | 8 |
| 2021 | 1 |
| 2020 | 4 |
| 2019 | 10 |
| 2018 | 8 |
| 2017 | 7 |
Showing 10 of 26 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 2 trials starting in 2026 and about 5 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tissue Adhesions trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 1/2 | 4 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 9 |
| Not applicable | 59 |
| Observational | 32 |
How many Tissue Adhesions trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 3 |
| Completed | 71 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Tissue Adhesions trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Shin Poong Pharmaceutical Co. Ltd. | 5 |
| Baxter Healthcare Corporation | 2 |
| Integra LifeSciences Corporation | 2 |
| National Institute of Dental and Craniofacial Research (NIDCR) | 2 |
| Pharmasyntez | 2 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Seprafilm | 2 |
| Seroguard | 2 |
| Liposomal Bupivacaine + Compound Betamethasone Injection | 1 |
| Low Heparin Molecular Weight | 1 |
| Sodium Hyaluronate 1% | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Tissue Adhesions trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Inververtebral disc protrusion | 17 | 1 |
| Tendon rupture | 11 | 1 |
| Vaso-occlusive crisis resulting in hospitalization | 7 | 1 |
| Cardiac Arrest unrelated to device | 4 | 1 |
| Headache | 3 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Tissue Adhesions? (443)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prediction of vesicouterine adhesions by transvaginal sonographic sliding sign technique: validation study. | Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology | 2025 | Yes |
| Long-term Inhibition of Soleus H-reflex with Epidural Adhesiolysis and Pulsed Radiofrequency in Lumbosacral Neuropathic Pain. | Pain practice : the official journal of World Institute of Pain | 2021 | Yes |
| A review of physiological and cellular mechanisms underlying fibrotic postoperative adhesion. | International journal of biological sciences | 2021 | Yes |
| SURGICAL OUTCOMES OF VITREOMACULAR TRACTION TREATED WITH FOVEAL-SPARING PEELING OF THE INTERNAL LIMITING MEMBRANE. | Retina (Philadelphia, Pa.) | 2021 | Yes |
| Effect of laser acupuncture on adhesive small bowel obstruction: A prospective double-blind randomized controlled trial. | Medicine | 2021 | Yes |
Showing 5 of 443 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.